Ace Vision Group Closes $29.4 Million Series B Financing Round

Ace Vision Group announced the successful close of a $29.4 million Series B financing round. The new capital will support the continued development of the company’s proprietary Gen II VisioLite Ophthalmic Laser, which delivers the minimally invasive LSM procedure—a treatment targeting the loss of Dynamic Range of Focus caused by presbyopia.

“This Series B funding marks a critical inflection point for our company,” said AnnMarie Hipsley, PhD, founder and CEO of Ace Vision Group, said in a company news release. “It enables us to finalize the research and design of our commercial system and positions us to initiate clinical trials both in the US and internationally. We remain on track to submit our 510(k) application in 2026.”

Ace Vision Group’s patented LSM technology aims to become the first laser-based, in-office therapeutic designed to treat progressive presbyopia by reducing age-related ocular rigidity. In a recent pilot study using a Gen I device, the procedure showed encouraging outcomes, with a majority of patients no longer requiring reading glasses after treatment, according to Ace Vision.

“There is a clear and growing demand for in-office, ultra-minimally invasive solutions that address the root cause of presbyopia while preserving patient convenience and clinical efficiency," Dr. Hipsley said. "AVG’s technology aligns directly with this unmet need, offering a scalable, procedure-based model that integrates seamlessly into ophthalmic practices. This level of market relatability, combined with strong clinical interest and favorable economics, positions us for broad adoption and long-term value creation."